Mike Rosinko

Chief Technology Officer

Mr. Rosinko has served as Chief Technology Officer since August 2020. He previously served as Vice President of Research and Development since January 2017. Prior to joining our company, Mr. Rosinko served as Vice President of Research and Development at Tandem Diabetes Care (NASDAQ: TNDM) where he led the technical team to develop and launch the t:slim insulin pump. He also has more than 20 years of experience in developing medical devices in the areas of electrophysiology, apheresis, laser cardiac surgery and contract engineering at Biosense Webster (NYSE: JNJ), Baxter Healthcare (NYSE: BAX), CardioGenesis (NYSE: CRY), and the Aubrey Group (NYSE:SPA) respectively. This experience allows him to bring with him the specialized knowledge necessary to gain regulatory approval and commercialize a novel pumping platform. Mr. Rosinko holds a Masters of Business Administration from Claremont Graduate University, a Masters of Science in Electrical Engineering from the University of Southern California, and a Bachelor of Science in Electrical Engineering from the University of Pittsburgh, where he graduated cum laude. In addition, he holds more than 40 issued US patents in medical systems and devices.

What drew you to work in the diabetes industry?

When I look at healthcare in the US and abroad, I cannot avoid the reality that diabetes, in all forms, is not well managed. There are few conditions with such a large and growing patient population to address where the current standard of patient care is simply not adequate. I see a tremendous opportunity to have an impact on a patient population and the families that live with this condition.

Why did you choose to work at Beta Bionics?

I was introduced to Ed Damiano in the Fall of 2014. At the time, Ed was looking to make some strategic decisions about the future of the bionic pancreas and how best to structure the iLet technology into a company that would lead to a commercial product. I have been involved with the team since that time. Ed’s passion and the vision for a better solution to type 1 diabetes treatment caught my attention in a profound way. Since then, the product development & clinical trial results has only bolstered my belief that Beta Bionics is working to transform the diabetes community. I am proud to contribute in any way I can.

What is the most rewarding part about working at Beta Bionics?

It is impossible to boil this question down to a single sound bite. The passion, the technology, the team, the ability and desire to think differently, our Public Benefit Corporation structure…I could go on. The ultimate reward, however, will be to see the iLet on patients and to transform the lives of those living with type 1 diabetes.

CAUTION: The iLet® bionic pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale.

© 2021 Beta Bionics, Inc. Beta Bionics® and iLet® are registered trademarks of Beta Bionics, Inc. All rights reserved. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation.